{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:11:22Z","timestamp":1794863482484,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41401-025-01572-0","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:23:50Z","timestamp":1746696230000},"page":"2849-2862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Generating potent and persistent antitumor immunity via affinity-tuned CAR-T cells targeting mesothelin"],"prefix":"10.1038","volume":"46","author":[{"given":"Ya-li","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-di","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-lin","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-sheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-dong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"1572_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01682-x","volume":"21","author":"P Nallasamy","year":"2022","unstructured":"Nallasamy P, Nimmakayala RK, Parte S, Are AC, Batra SK, Ponnusamy MP. Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis. Mol Cancer. 2022;21:225.","journal-title":"Mol Cancer"},{"key":"1572_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635\u201348.","journal-title":"Nature"},{"key":"1572_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s43018-021-00241-5","volume":"2","author":"MC Milone","year":"2021","unstructured":"Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ Jr, et al. Engineering enhanced CAR T-cells for improved cancer therapy. Nat Cancer. 2021;2:780\u201393.","journal-title":"Nat Cancer"},{"key":"1572_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216355","volume":"572","author":"X Zhang","year":"2023","unstructured":"Zhang X, Guo H, Chen J, Xu C, Wang L, Ke Y, et al. Highly proliferative and hypodifferentiated CAR-T cells targeting B7-H3 enhance antitumor activity against ovarian and triple-negative breast cancers. Cancer Lett. 2023;572:216355.","journal-title":"Cancer Lett"},{"key":"1572_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med."},{"key":"1572_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103.","journal-title":"Lancet Oncol"},{"key":"1572_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2021014892","volume":"140","author":"NV Frey","year":"2022","unstructured":"Frey NV. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood. 2022;140:11\u20135.","journal-title":"Blood"},{"key":"1572_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"Abramson","year":"2020","unstructured":"Abramson, Palomba JS, Gordon LI ML, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"1572_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med."},{"key":"1572_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1572_CR11","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391:2219\u201330.","journal-title":"N Engl J Med."},{"key":"1572_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21:1089\u2013108.","journal-title":"Cell Mol Immunol"},{"key":"1572_CR13","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/cancers14061550","volume":"14","author":"JR Faust","year":"2022","unstructured":"Faust JR, Hamill D, Kolb EA, Gopalakrishnapillai A, Barwe SP. Mesothelin: an immunotherapeutic target beyond solid tumors. Cancers (Basel). 2022;14:1550.","journal-title":"Cancers (Basel)"},{"key":"1572_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3892\/ol.2020.12055","volume":"20","author":"T Suzuki","year":"2020","unstructured":"Suzuki T, Yamagishi Y, Einama T, Koiwai T, Yamasaki T, Fukumura-Koga M, et al. Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer. Oncol Lett. 2020;20:193.","journal-title":"Oncol Lett"},{"key":"1572_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","volume":"21","author":"A Klampatsa","year":"2021","unstructured":"Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473\u201386.","journal-title":"Expert Opin Biol Ther"},{"key":"1572_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA, et al. Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther. 2019;27:1919\u201329.","journal-title":"Mol Ther"},{"key":"1572_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26\u201331.","journal-title":"Cancer Immunol Res"},{"key":"1572_CR18","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Riviere I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11:2748\u201363.","journal-title":"Cancer Discov"},{"key":"1572_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"1572_CR20","doi-asserted-by":"publisher","first-page":"e008989","DOI":"10.1136\/jitc-2024-008989","volume":"12","author":"D Li","year":"2024","unstructured":"Li D, Liang T, Hutchins LE, Wolfarth AA, Ferrando-Martinez S, Lee BH, et al. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. J Immunother Cancer. 2024;12:e008989.","journal-title":"J Immunother Cancer"},{"key":"1572_CR21","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D, Ghatwai N, Montalbano A, Rathi P, Courtney AN, Arnett AB, et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025;637:940\u20136.","journal-title":"Nature"},{"key":"1572_CR22","doi-asserted-by":"publisher","first-page":"e002173","DOI":"10.1136\/jitc-2020-002173","volume":"9","author":"G Wang","year":"2021","unstructured":"Wang G, Zhou X, Fuca G, Dukhovlinova E, Shou P, Li H, et al. Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors. J Immunother Cancer. 2021;9:e002173.","journal-title":"J Immunother Cancer"},{"key":"1572_CR23","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","volume":"158","author":"D Li","year":"2020","unstructured":"Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology. 2020;158:2250\u201365.e20.","journal-title":"Gastroenterology"},{"key":"1572_CR24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202439119","volume":"119","author":"X Liu","year":"2022","unstructured":"Liu X, Onda M, Watson N, Hassan R, Ho M, Bera TK, et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proc Natl Acad Sci USA. 2022;119:e2202439119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1572_CR25","doi-asserted-by":"publisher","first-page":"e010083","DOI":"10.1136\/jitc-2024-010083","volume":"13","author":"T Inthanachai","year":"2025","unstructured":"Inthanachai T, Boonkrai C, Phakham T, Pisitkun T, Thaiwong R, Chuthaphakdikun V, et al. Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study. J Immunother Cancer. 2025;13:e010083.","journal-title":"J Immunother Cancer"},{"key":"1572_CR26","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6:261ra151.","journal-title":"Sci Transl Med"},{"key":"1572_CR27","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126:3130\u201344.","journal-title":"J Clin Invest"},{"key":"1572_CR28","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","volume":"81","author":"E Schoutrop","year":"2021","unstructured":"Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, et al. Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res. 2021;81:3022\u201335.","journal-title":"Cancer Res"},{"key":"1572_CR29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jcyt.2024.01.011","volume":"26","author":"GJ Chu","year":"2024","unstructured":"Chu GJ, Bailey CG, Nagarajah R, Liang O, Metierre C, Sagnella SM, et al. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity. Cytotherapy. 2024;26:325\u201333.","journal-title":"Cytotherapy"},{"key":"1572_CR30","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1038\/s41401-024-01316-6","volume":"45","author":"JJ Liu","year":"2024","unstructured":"Liu JJ, Pan ZD, Yue YL, Wang SS, Chen J, Jiang H, et al. T cell-redirecting antibody for treatment of solid tumors via targeting mesothelin. Acta Pharmacol Sin. 2024;45:2186\u201398.","journal-title":"Acta Pharmacol Sin."},{"key":"1572_CR31","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol Ther. 2023;31:2309\u201325.","journal-title":"Mol Ther"},{"key":"1572_CR32","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","volume":"8","author":"Y Feng","year":"2009","unstructured":"Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther. 2009;8:1113\u20138.","journal-title":"Mol Cancer Ther"},{"key":"1572_CR33","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1158\/0008-5472.CAN-15-0139","volume":"75","author":"HG Caruso","year":"2015","unstructured":"Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75:3505\u201318.","journal-title":"Cancer Res"},{"key":"1572_CR34","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.2021013289","volume":"139","author":"M Shadman","year":"2022","unstructured":"Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330\u20139.","journal-title":"Blood"},{"key":"1572_CR35","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.immuni.2023.01.003","volume":"56","author":"F Sacirbegovic","year":"2023","unstructured":"Sacirbegovic F, Gunther M, Greco A, Zhao D, Wang X, Zhou M, et al. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity. 2023;56:369\u201385.e6.","journal-title":"Immunity"},{"key":"1572_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165404","volume":"14","author":"H Shi","year":"2023","unstructured":"Shi H, Li A, Dai Z, Xue J, Zhao Q, Tian J, et al. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models. Front Immunol. 2023;14:1165404.","journal-title":"Front Immunol"},{"key":"1572_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020;11:549\u201364.","journal-title":"Protein Cell"},{"key":"1572_CR38","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21:2122\u20139.","journal-title":"Mol Ther"},{"key":"1572_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-07934-1","volume":"21","author":"Z Ying","year":"2021","unstructured":"Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, et al. Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. BMC Cancer. 2021;21:198.","journal-title":"BMC Cancer"},{"key":"1572_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602:503\u20139.","journal-title":"Nature"},{"key":"1572_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1572_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17960","volume":"9","author":"J Chen","year":"2023","unstructured":"Chen J, Pan Z, Han L, Liu J, Yue Y, Xiao X, et al. Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies. Heliyon. 2023;9:e17960.","journal-title":"Heliyon"},{"key":"1572_CR43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2767-9764.CRC-22-0306","volume":"3","author":"J Zhan","year":"2023","unstructured":"Zhan J, Lin D, Watson N, Esser L, Tang WK, Zhang A, et al. Structures of cancer antigen mesothelin and its complexes with therapeutic antibodies. Cancer Res Commun. 2023;3:175\u201391.","journal-title":"Cancer Res Commun"},{"key":"1572_CR44","doi-asserted-by":"publisher","first-page":"e008659","DOI":"10.1136\/jitc-2023-008659","volume":"12","author":"T Gargett","year":"2024","unstructured":"Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A, et al. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers. J Immunother Cancer. 2024;12:e008659.","journal-title":"J Immunother Cancer"},{"key":"1572_CR45","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-18-2559","volume":"25","author":"E Drent","year":"2019","unstructured":"Drent E, Poels R, Ruiter R, van de Donk N, Zweegman S, Yuan H, et al. Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor-engineered T cells. Clin Cancer Res. 2019;25:4014\u201325.","journal-title":"Clin Cancer Res"},{"key":"1572_CR46","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492\u2013500.","journal-title":"Leukemia"},{"key":"1572_CR47","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353.","journal-title":"JAMA Oncol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01572-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01572-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01572-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T22:03:20Z","timestamp":1758751400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01572-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1572"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01572-0","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZDP is an employee of Jecho Institute Co., Ltd. (Shanghai, China). SSW, YQX, HJ, and XDX are employees of Jecho Laboratories, Inc. (Frederick, MD, USA). No potential conflicts of interest were disclosed by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}